Literature DB >> 28537788

The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature.

Mark Dunphy1, Neeta Pandit-Taskar1, Josef J Fox1, Nancy Kemeny2.   

Abstract

OBJECTIVE: Optimal clinical development of new cancer therapies targeting tumor vasculature requires new target-specific response assays. This clinical study examined the test-retest repeatability of SPECT as an in vivo assay of angiogenic hepatic tumor microvasculature using an intraarterial infusion of 99mTc-macroaggregated albumin (MAA) delivered via a hepatic artery infusion (HAI) pump.
MATERIALS AND METHODS: Patients with primary or secondary cancerous liver tumors with HAI pump-catheter implants placed for HAI chemotherapy underwent hepatic SPECT after separate arterial infusions of 37 and 185 MBq of 99mTc-MAA via an HAI pump. Quantitative measures of hepatic tumor MAA uptake were obtained from paired test-retest SPECT datasets. Repeatability was defined by quotients of paired measurands with 95% CIs and coefficients of repeatability (CRs).
RESULTS: Test-retest HAI pump SPECT yielded highly repeatable measurements in quantitative indexes of tumor microvasculature. Variability in repeat test-retest measurements was small relative to the range of observed measurements between different tumors. The total hepatic tumor microvascular MAA accumulation (percentage injected dose) proved most repeatable, with test-retest value quotients near unity (quotients: median, 1.10 ± 0.09 [SD]; range, 1.03-1.32; 95% CI, 1.07-1.19) and 1.6% CR. Tumor MAA uptake values ranged from 5% to 18% injected dose.
CONCLUSION: This article describes the precision of HAI SPECT as a quantitative biomarker of tumor microvasculature under conditions of repeatability. The results support clinical testing of HAI SPECT as a radiologic response biomarker for angiotropic tumor therapy.

Entities:  

Keywords:  angiogenesis inhibitors; liver neoplasms; microspheres; neovascularization; pathologic neovascularization; yttrium radioisotopes

Mesh:

Substances:

Year:  2017        PMID: 28537788      PMCID: PMC5577942          DOI: 10.2214/AJR.16.17560

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  33 in total

1.  Particle size and its mathematical distribution in six human albumin macroaggregate (MAA) kits.

Authors:  J Mallol; R V Diaz
Journal:  Nucl Med Commun       Date:  1997-01       Impact factor: 1.690

2.  Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver.

Authors:  E Watkins; A M Khazei; K S Nahra
Journal:  Surg Gynecol Obstet       Date:  1970-04

3.  Radionuclide angiography to predict patient response to hepatic artery chemotherapy.

Authors:  W D Kaplan; W D Ensminger; S E Come; E H Smith; C J D'Orsi; D C Levin; R W Takvorian; G D Steele
Journal:  Cancer Treat Rep       Date:  1980

4.  Intra-arterial radionuclide infusion: a new technique to assess chemotherapy perfusion patterns.

Authors:  W D Kaplan; C J D'Orsi; W D Ensminger; E H Smith; D C Levin
Journal:  Cancer Treat Rep       Date:  1978-05

5.  The effect of angiotensin II on tumor blood flow and the delivery of microparticulate cytotoxic drugs.

Authors:  D J Kerr; J A Goldberg; J R Anderson; N Wilmott; A T Whatelely; C S McArdle; J Mckillop
Journal:  EXS       Date:  1992

6.  Predicting tumor response in patients with colorectal hepatic metastases.

Authors:  J M Daly; J Butler; N Kemeny; S D Yeh; J A Ridge; J Botet; J R Bading; J J DeCosse; R S Benua
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

7.  Single photon emission computed tomographic studies (SPECT) of hepatic arterial perfusion scintigraphy (HAPS) in patients with colorectal liver metastases: improved tumour targetting by microspheres with angiotensin II.

Authors:  J A Goldberg; M S Bradnam; D J Kerr; J H McKillop; R G Bessent; C S McArdle; N Willmott; W D George
Journal:  Nucl Med Commun       Date:  1987-12       Impact factor: 1.690

8.  Diagnostic pharmaco-scintigraphy with hepatic intra-arterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma.

Authors:  W Y Lau; T W Leung; S Ho; M Chan; N W Leung; J Lin; C Metreweli; A K Li
Journal:  Br J Radiol       Date:  1994-02       Impact factor: 3.039

9.  99mTc-labeled macroaggregated albumin in intrahepatic arterial chemotherapy.

Authors:  A G Bledin; H M Kantarjian; E E Kim; S Wallace; V P Chuang; Y Z Patt; T P Haynie
Journal:  AJR Am J Roentgenol       Date:  1982-10       Impact factor: 3.959

10.  The case for using the repeatability coefficient when calculating test-retest reliability.

Authors:  Sharmila Vaz; Torbjörn Falkmer; Anne Elizabeth Passmore; Richard Parsons; Pantelis Andreou
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.